NovoCure Dividends and Buybacks
Dividend criteria checks 0/6
NovoCure does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-0.2%
Buyback Yield
| Total Shareholder Yield | -0.2% |
| Future Dividend Yield | n/a |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Feb 12
NovoCure Limited (NASDAQ:NVCR) Looks Just Right With A 84% Price Jump
Dec 03Novocure Moves Pancreatic Cancer Treatment Forward With A 'First' Using TTFields
Dec 02Analyst Estimates: Here's What Brokers Think Of NovoCure Limited (NASDAQ:NVCR) After Its Third-Quarter Report
Nov 01Is NovoCure (NASDAQ:NVCR) A Risky Investment?
Oct 17NovoCure: There Is Still More Upside
Oct 16NovoCure's Stock Stagnates Amid Lack Of Progress Beyond GBM
Oct 09Investors Appear Satisfied With NovoCure Limited's (NASDAQ:NVCR) Prospects
Sep 12NovoCure Limited: A Post Q2 Analysis
Jul 26NovoCure Limited Q1 Earnings: Core Business Accelerating
May 03NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry?
Apr 08NovoCure: Sell The METIS-Inspired Rally
Mar 28Some Shareholders Feeling Restless Over NovoCure Limited's (NASDAQ:NVCR) P/S Ratio
Mar 03NovoCure: Stay Cautious Amid Positive Signs
Jan 19Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Nov 16Is NovoCure (NASDAQ:NVCR) Weighed On By Its Debt Load?
Aug 13Is NovoCure (NASDAQ:NVCR) A Risky Investment?
May 15A Look At The Intrinsic Value Of NovoCure Limited (NASDAQ:NVCR)
Apr 24Why NovoCure Limited (NASDAQ:NVCR) Could Be Worth Watching
Feb 10Does NovoCure (NASDAQ:NVCR) Have A Healthy Balance Sheet?
Jan 16Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if NVCR's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NVCR's dividend payments have been increasing.
Dividend Yield vs Market
| NovoCure Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (NVCR) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.4% |
| Industry Average (Medical Equipment) | 1.6% |
| Analyst forecast (NVCR) (up to 3 years) | n/a |
Notable Dividend: Unable to evaluate NVCR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NVCR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate NVCR's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NVCR has not reported any payouts.
Discover strong dividend paying companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/16 11:49 |
| End of Day Share Price | 2025/02/14 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
NovoCure Limited is covered by 14 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Gilbert | Deutsche Bank |
| Vijay Kumar | Evercore ISI |
| Emily Bodnar | H.C. Wainwright & Co. |